Work

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors

Year: 2026

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-026-01626-y

Authors: Daruka Mahadevan, Jay Parekh, Joseph T. Beck, Willam B. McKean, Karisa C. Schreck, Anthony J. Olszanski, Misty D. Shields, Vu Phan, John T. Hamm, Bruce B. Bank, Jianli Zhou, Marc Chamberlain, Kishor Bhatia, Reginald Ewesuedo

Institutions: The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, South Texas Accelerated Research Therapeutics, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Fox Chase Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Norton Healthcare, NF-kappaB, Différenciation et Cancer

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7167487687

FWCI: 2.08

Cites: 19

Cited by: 1

Related to: 10